Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | ANDROMEDA: daratumumab for AL amyloidosis

Angela Dispenzieri • 31 May 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Cyclophosphamide Daratumumab Dexamethasone
ANDROMEDA

Angela Dispenzieri, MD, of the Mayo Clinic College of Medicine, Rochester, MN, discusses the use of daratumumab for amyloid light-chain (AL) amyloidosis and clinical trials evaluating its use. Specifically highlighted is the ANDROMEDA study (NCT03201965), as well as prospective trials in the relapsed/refractory setting. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Angela Dispenzieri

Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria 1:53
Unmet needs in amyloidosis: early diagnosis, treating relapsed disease & progression criteria
Angela Dispenzieri • 6 Sep 2023
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits 2:30
Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri • 6 Sep 2023
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease 1:42
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease
Angela Dispenzieri • 6 Sep 2023
Rationale behind the watch and wait strategy in smoldering myeloma 1:57
Rationale behind the watch and wait strategy in smoldering myeloma
Angela Dispenzieri • 6 Sep 2023

Related Videos

Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025
Ongoing research in gray zone lymphoma 1:07
Ongoing research in gray zone lymphoma
Kieron Dunleavy • 4 Sep 2025
Insights into gray zone lymphoma: a rare subtype of NHL 1:14
Insights into gray zone lymphoma: a rare subtype of NHL
Kieron Dunleavy • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals